Global osteoporosis treatment market is estimated to be valued at USD 14.91 Bn in 2024, and is expected to exhibit a CAGR of 4.2% during the forecast period (2024-2031). Osteoporosis is a condition characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility and an increased risk of fractures. The disease has become a major global healthcare concern, especially among the elderly population. Factors such as increasing life expectancy, sedentary lifestyles, and improper nutrition have contributed significantly to rising prevalence of osteoporosis across both developed and developing nations. According to data published by Frontiers, over 200 million people worldwide suffer from osteoporosis. With no curative treatment currently available, lifelong management through pharmacotherapy plays a crucial role in treatment and prevention of fractures. Global osteoporosis treatment market has witnessed steady growth over the past couple of decades to meet this unmet need.

Market Dynamics:

Growing geriatric population who are at high risk of osteoporosis is expected to boost demand for osteoporosis treatment drugs globally. According to the United Nations, the population aged 65 years and above is expected to more than double by 2050. Rising awareness about osteoporosis screening and management, new product launches, and increasing at-risk patient diagnosis are further propelling the market growth. However, patent expiries of blockbuster drugs and preference for generic drugs continue to restrain the market growth. Meanwhile, significant opportunities lie in emerging economies due to growing accessibility of healthcare.

Key Features of the Study:

• This report provides an in-depth analysis of the global osteoporosis treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global osteoporosis treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED, Amgen Inc., Dr. Reddy’s Laboratories Ltd., Viatris Inc., Ligand Pharmaceuticals Incorporated, Eli Lilly and Company, Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd, EffRx Pharmaceuticals SA, Novartis AG, Merck & Co., Inc., GSK plc., Pfizer Inc., Enzene Biosciences, Apotex Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global osteoporosis treatment market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global osteoporosis treatment market.

Detailed Segmentation-

• By Drug Type:
  • Bisphosphonates 
  • Calcitonin, Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Others
• By Route of Administration:
  • Oral
  • Injectable
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

Company Profiles:

• Teva Pharmaceutical Industries Ltd.
• DAIICHI SANKYO COMPANY, LIMITED
• Amgen Inc.
• Reddy’s Laboratories Ltd.
• Viatris Inc.
• Ligand Pharmaceuticals Incorporated
• Eli Lilly and Company
• Asahi Kasei Corporation
• Hoffmann-La Roche Ltd
• EffRx Pharmaceuticals SA
• Novartis AG
• Merck & Co., Inc.
• GSK plc.
• Pfizer Inc.
• Enzene Biosciences
• Apotex Inc.